Hepatocellular carcinoma
Not recruitingStudy of Atezolizumab with Lenvatinib or Sorafenib vs Lenvatinib or Sorafenib alone in Unresectable Hepatocellular Carcinoma after Atezolizumab and Bevacizumab
Study of Atezolizumab with Lenvatinib or Sorafenib vs Lenvatinib or Sorafenib alone in Unresectable Hepatocellular Carcinoma after Atezolizumab and Bevacizumab
- Disease:Hepatocellular carcinoma
- Substances:AtezolizumabLenvatinib+1
Belgium- Participants:18–64 years · 65+ years
- Substances:Atezolizumab
- Sponsor:F. Hoffmann-La Roche AG













